{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:25:33Z","timestamp":1768490733033,"version":"3.49.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>We provide an overview of cardiac metabolism, ketone physiology and terminology, methods of elevating ketones and their effect on cardiac function and disease. We discuss future research directions and speculate what ketogenic strategies may yield optimal effects on the heart and cardiovascular disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Nutritional ketosis acutely elevates cardiac function (cardiac output, myocardial perfusion, etc.) in healthy people and those with cardiovascular disease in a dose-dependent manner between circulating ketones and cardiac function. Despite therapeutic potential, long-term studies have not been performed. This acute effect is rapid, dose-dependent, and has been seen to be durable for up to 14 days following intervention onset.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There are numerous methods to elicit ketogenesis and promote nutritional ketosis. There is growing evidence to suggest that higher ketone levels may offer greater cardiac benefits. It is pertinent to consider what ketone levels to target, and the best methods to safely and feasibly reach those targets over sustained periods of time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11883-025-01333-8","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:39:26Z","timestamp":1756363166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Salutary Effects of Nutritional Ketosis for the Diseased Human Heart"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-3048","authenticated-orcid":false,"given":"Christopher D.","family":"Crabtree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Buga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando P.","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff S.","family":"Volek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"1333_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103299","volume":"13","author":"JS Volek","year":"2021","unstructured":"Volek JS, Phinney SD, Krauss RM, Johnson RJ, Saslow LR, Gower B, et al. Alternative dietary patterns for Americans: low-carbohydrate diets. Nutrients. 2021;13: 13:3299.","journal-title":"Nutrients"},{"key":"1333_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005066","volume":"6","author":"LC Gormsen","year":"2017","unstructured":"Gormsen LC, Svart M, Thomsen HH, S\u00f8ndergaard E, Vendelbo MH, Christensen N, et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc. 2017;6: e005066.","journal-title":"J Am Heart Assoc"},{"key":"1333_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129\u201341.","journal-title":"Circulation"},{"key":"1333_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207\u201358.","journal-title":"Physiol Rev"},{"key":"1333_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev.ph.36.030174.002213","volume":"36","author":"JR Neely","year":"1974","unstructured":"Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol. 1974;36:413\u201359.","journal-title":"Annu Rev Physiol"},{"key":"1333_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.bbalip.2016.03.014","volume":"1860","author":"F Pascual","year":"2016","unstructured":"Pascual F, Coleman RA. Fuel availability and fate in cardiac metabolism: a tale of two substrates. Biochim Biophys Acta. 2016;1860:1425\u201333.","journal-title":"Biochim Biophys Acta"},{"key":"1333_CR7","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093\u2013129.","journal-title":"Physiol Rev"},{"key":"1333_CR8","doi-asserted-by":"crossref","unstructured":"Kolwicz SC Jr. An exercise in cardiac metabolism. Front Cardiovasc Med. 2018;5: 66.","DOI":"10.3389\/fcvm.2018.00066"},{"key":"1333_CR9","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2020.12.065","volume":"77","author":"SR Yurista","year":"2021","unstructured":"Yurista SR, Chong C-R, Badimon JJ, Kelly DP, de Boer RA, Westenbrink BD. Therapeutic potential of ketone bodies for patients with cardiovascular disease: JACC State-of-the-Art review. J Am Coll Cardiol. 2021;77:1660\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1333_CR10","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.tem.2021.07.006","volume":"32","author":"SR Yurista","year":"2021","unstructured":"Yurista SR, Nguyen CT, Rosenzweig A, de Boer RA, Westenbrink BD. Ketone bodies for the failing heart: fuels that can fix the engine? Trends Endocrinol Metab. 2021;32:814\u201326.","journal-title":"Trends Endocrinol Metab"},{"key":"1333_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/0022-2828(95)90000-4","volume":"27","author":"AM Gerdes","year":"1995","unstructured":"Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 1995;27:849\u201356.","journal-title":"J Mol Cell Cardiol"},{"key":"1333_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018;15:457\u201370.","journal-title":"Nat Rev Cardiol"},{"key":"1333_CR13","doi-asserted-by":"publisher","first-page":"H3270","DOI":"10.1152\/ajpheart.00887.2007","volume":"293","author":"D Neglia","year":"2007","unstructured":"Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;293:H3270\u20138.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1333_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.004953","volume":"11","author":"G Voros","year":"2018","unstructured":"Voros G, Ector J, Garweg C, Droogne W, Van Cleemput J, Peersman N, et al. Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling. Circ Heart Fail. 2018;11: e004953.","journal-title":"Circ Heart Fail"},{"key":"1333_CR15","doi-asserted-by":"publisher","first-page":"H1538","DOI":"10.1152\/ajpheart.00281.2004","volume":"287","author":"MP Chandler","year":"2004","unstructured":"Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2004;287:H1538\u201343.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1333_CR16","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","volume":"94","author":"MN Sack","year":"1996","unstructured":"Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837\u201342.","journal-title":"Circulation"},{"key":"1333_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cvr\/cvr038","volume":"90","author":"V Lionetti","year":"2011","unstructured":"Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res. 2011;90:202\u20139.","journal-title":"Cardiovasc Res"},{"key":"1333_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1161\/CIRCULATIONAHA.120.052671","volume":"143","author":"AN Carley","year":"2021","unstructured":"Carley AN, Maurya SK, Fasano M, Wang Y, Selzman CH, Drakos SG, et al. Short-chain fatty acids outpace ketone oxidation in the failing heart. Circulation. 2021;143:1797\u2013808.","journal-title":"Circulation"},{"key":"1333_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0005-x","volume":"24","author":"N Fillmore","year":"2018","unstructured":"Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, et al. Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction. Mol Med. 2018;24: 3.","journal-title":"Mol Med"},{"key":"1333_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0735-1097(02)01967-8","volume":"40","author":"D \u00e1vila-RVG","year":"2002","unstructured":"\u00e1vila-RVG D, Vedala G, Herrero P, de las FL, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"1333_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.81.2.153","volume":"81","author":"Y Yazaki","year":"1999","unstructured":"Yazaki Y, Isobe M, Takahashi W, Kitabayashi H, Nishiyama O, Sekiguchi M, et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart. 1999;81:153\u20139.","journal-title":"Heart"},{"key":"1333_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.abc8861","volume":"370","author":"D Murashige","year":"2020","unstructured":"Murashige D, Jang C, Neinast M, Edwards JJ, Cowan A, Hyman MC, et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science. 2020;370:364\u20138.","journal-title":"Science"},{"key":"1333_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0735-1097(97)00185-X","volume":"30","author":"JW Swan","year":"1997","unstructured":"Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"1333_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/CIRCRESAHA.116.306206","volume":"118","author":"C Riehle","year":"2016","unstructured":"Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res. 2016;118:1151\u201369.","journal-title":"Circ Res"},{"key":"1333_CR25","doi-asserted-by":"crossref","unstructured":"Abel ED, O\u2019Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arteriosclerosis, thrombosis, and vascular biology. 2012;32:2068\u201376","DOI":"10.1161\/ATVBAHA.111.241984"},{"key":"1333_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","volume":"25","author":"P Puchalska","year":"2017","unstructured":"Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25:262\u201384.","journal-title":"Cell Metab"},{"key":"1333_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/bj1720377","volume":"172","author":"AP Halestrap","year":"1978","unstructured":"Halestrap AP. Pyruvate and ketone-body transport across the mitochondrial membrane. Exchange properties, pH-dependence and mechanism of the carrier. Biochem J. 1978;172:377\u201387.","journal-title":"Biochem J"},{"key":"1333_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11897-022-00554-1","volume":"19","author":"SR Yurista","year":"2022","unstructured":"Yurista SR, Chen S, Welsh A, Tang WHW, Nguyen CT. Targeting myocardial substrate metabolism in the failing heart: ready for prime time?? Curr Heart Fail Rep. 2022;19:180\u201390.","journal-title":"Curr Heart Fail Rep"},{"key":"1333_CR29","doi-asserted-by":"publisher","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","volume":"304","author":"DG Cotter","year":"2013","unstructured":"Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304:H1060-76.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1333_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154452","volume":"115","author":"L Monzo","year":"2021","unstructured":"Monzo L, Sedlacek K, Hromanikova K, Tomanova L, Borlaug BA, Jabor A, et al. Myocardial ketone body utilization in patients with heart failure: the impact of oral ketone ester. Metabolism. 2021;115: 154452.","journal-title":"Metabolism"},{"key":"1333_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","volume":"24","author":"GD Lopaschuk","year":"2016","unstructured":"Lopaschuk GD, Verma S. Empagliflozin\u2019s fuel hypothesis: not so soon. Cell Metab. 2016;24:200\u20132.","journal-title":"Cell Metab"},{"key":"1333_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/01.RES.41.6.849","volume":"41","author":"C Steenbergen","year":"1977","unstructured":"Steenbergen C, Deleeuw G, Rich T, Williamson JR. Effects of acidosis and ischemia on contractility and intracellular pH of rat heart. Circ Res. 1977;41:849\u201358.","journal-title":"Circ Res"},{"key":"1333_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/1050-1738(93)90022-X","volume":"3","author":"S Schiaffino","year":"1993","unstructured":"Schiaffino S, Gorza L, Ausoni S. Troponin isoform switching in the developing heart and its functional consequences. Trends Cardiovasc Med. 1993;3:12\u20137.","journal-title":"Trends Cardiovasc Med"},{"key":"1333_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s44161-023-00259-1","volume":"2","author":"GD Lopaschuk","year":"2023","unstructured":"Lopaschuk GD, Dyck JRB. Ketones and the cardiovascular system. Nat Cardiovasc Res. 2023;2:425\u201337.","journal-title":"Nat Cardiovasc Res"},{"key":"1333_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114753","volume":"14","author":"E-M Weis","year":"2022","unstructured":"Weis E-M, Puchalska P, Nelson AB, Taylor J, Moll I, Hasan SS, et al. Ketone body oxidation increases cardiac endothelial cell proliferation. EMBO Mol Med. 2022;14: e14753.","journal-title":"EMBO Mol Med"},{"key":"1333_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.yjmcc.2010.09.014","volume":"50","author":"H Taegtmeyer","year":"2011","unstructured":"Taegtmeyer H, Stanley WC. Too much or not enough of a good thing?? Cardiac glucolipotoxity versus lipoprotection. J Mol Cell Cardiol. 2011;50:2.","journal-title":"J Mol Cell Cardiol"},{"key":"1333_CR37","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/cvr\/cvaa298","volume":"117","author":"M Nakamura","year":"2021","unstructured":"Nakamura M, Odanovic N, Nakada Y, Dohi S, Zhai P, Ivessa A, et al. Dietary carbohydrates restriction inhibits the development of cardiac hypertrophy and heart failure. Cardiovasc Res. 2021;117:2365\u201376.","journal-title":"Cardiovasc Res"},{"key":"1333_CR38","doi-asserted-by":"crossref","unstructured":"Batch JT, Lamsal SP, Adkins M, Sultan S, Ramirez MN. Advantages and disadvantages of the ketogenic diet: a review article. Cureus. 2020;12:e9639.","DOI":"10.7759\/cureus.9639"},{"key":"1333_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","volume":"15","author":"L Laffel","year":"1999","unstructured":"Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diab\/Metab Res Rev. 1999;15:412\u201326.","journal-title":"Diab\/Metab Res Rev"},{"key":"1333_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00198-z","volume":"8","author":"TV Luong","year":"2023","unstructured":"Luong TV, Nielsen EN, Falborg L, Kj\u00e6rulff MLG, Tolbod LP, S\u00f8ndergaard E, et al. Intravenous and oral whole body ketone dosimetry, biodistribution, metabolite correction and kinetics studied by (R)-[1-11C]\u03b2-hydroxybutyrate ([11C]OHB) PET in healthy humans. EJNMMI Radiopharm Chem. 2023;8: 12.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1333_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","volume":"25","author":"JC Newman","year":"2014","unstructured":"Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25:42\u201352.","journal-title":"Trends Endocrinol Metab"},{"key":"1333_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"Y-H Youm","year":"2015","unstructured":"Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. Ketone body \u03b2-hydroxybutyrate blocks the NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263\u20139.","journal-title":"Nat Med"},{"key":"1333_CR43","first-page":"e006573","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Soni S, Takahara S, Ferdaoussi M, Al Batran R, Darwesh AM, et al. Chronically elevating Circulating ketones can reduce cardiac inflammation and blunt the development of heart failure. Circulation: Heart Fail. 2020;13:e006573.","journal-title":"Circulation: Heart Fail"},{"key":"1333_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.metabol.2015.10.028","volume":"65","author":"JS Volek","year":"2016","unstructured":"Volek JS, Freidenreich DJ, Saenz C, Kunces LJ, Creighton BC, Bartley JM, et al. Metabolic characteristics of keto-adapted ultra-endurance runners. Metabolism. 2016;65:100\u201310.","journal-title":"Metabolism"},{"key":"1333_CR45","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1093\/milmed\/usz046","volume":"184","author":"RA LaFountain","year":"2019","unstructured":"LaFountain RA, Miller VJ, Barnhart EC, Hyde PN, Crabtree CD, McSwiney FT, et al. Extended ketogenic diet and physical training intervention in military personnel. Mil Med. 2019;184:e538\u201347.","journal-title":"Mil Med"},{"key":"1333_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.orcp.2007.11.003","volume":"2","author":"P Sumithran","year":"2008","unstructured":"Sumithran P, Proietto J. Ketogenic diets for weight loss: a review of their principles, safety and efficacy. Obes Res Clin Pract. 2008;2:1\u201313.","journal-title":"Obes Res Clin Pract"},{"key":"1333_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41387-020-00142-z","volume":"10","author":"X Yuan","year":"2020","unstructured":"Yuan X, Wang J, Yang S, Gao M, Cao L, Li X, et al. Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis. Nutr Diabetes. 2020;10:1\u20138.","journal-title":"Nutr Diabetes"},{"key":"1333_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s13300-018-0373-9","volume":"9","author":"SJ Hallberg","year":"2018","unstructured":"Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther. 2018;9:583\u2013612.","journal-title":"Diabetes Ther"},{"key":"1333_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101418","volume":"69","author":"APP Calimag","year":"2023","unstructured":"Calimag APP, Chlebek S, Lerma EV, Chaiban JT. Diabetic ketoacidosis. Dis Mon. 2023;69: 101418.","journal-title":"Dis Mon"},{"key":"1333_CR50","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s13668-024-00548-6","volume":"13","author":"JS Volek","year":"2024","unstructured":"Volek JS, Kackley ML, Buga A. Nutritional considerations during major weight loss therapy: focus on optimal protein and a low-carbohydrate dietary pattern. Curr Nutr Rep. 2024;13:422\u201343.","journal-title":"Curr Nutr Rep"},{"key":"1333_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11745-008-3274-2","volume":"44","author":"JS Volek","year":"2009","unstructured":"Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44:297\u2013309.","journal-title":"Lipids"},{"key":"1333_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01178-2","volume":"19","author":"SJ Athinarayanan","year":"2020","unstructured":"Athinarayanan SJ, Hallberg SJ, McKenzie AL, Lechner K, King S, McCarter JP, et al. Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19: 208.","journal-title":"Cardiovasc Diabetol"},{"key":"1333_CR53","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1333_CR54","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317.","journal-title":"Diabetologia"},{"key":"1333_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nut.2010.07.021","volume":"27","author":"S Cunnane","year":"2011","unstructured":"Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, et al. Brain fuel metabolism, aging, and Alzheimer\u2019s disease. Nutrition. 2011;27:3\u201320.","journal-title":"Nutrition"},{"key":"1333_CR56","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/alz.12206","volume":"17","author":"M Fortier","year":"2021","unstructured":"Fortier M, Castellano C-A, St-Pierre V, Myette-C\u00f4t\u00e9 \u00c9, Langlois F, Roy M, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement. 2021;17:543\u201352.","journal-title":"Alzheimers Dement"},{"key":"1333_CR57","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.70208","volume":"13","author":"CD Crabtree","year":"2025","unstructured":"Crabtree CD, Pan Y, Chandrasekaran P, Wang Y, Scandling D, Bedell T, et al. A ketogenic-promoting beverage acutely elevates cardiac function and myocardial blood flow compared to placebo in adults: a cardiac MRI investigation. Physiol Rep. 2025;13: e70208.","journal-title":"Physiol Rep"},{"key":"1333_CR58","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1139\/apnm-2018-0860","volume":"44","author":"Y Takahashi","year":"2019","unstructured":"Takahashi Y, Terada S, Banjo M, Seike K, Nakano S, Hatta H. Effects of \u03b2-hydroxybutyrate treatment on glycogen repletion and its related signaling cascades in epitrochlearis muscle during 120 min of postexercise recovery. Appl Physiol Nutr Metab. 2019;44:1311\u20139.","journal-title":"Appl Physiol Nutr Metab"},{"key":"1333_CR59","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211\u20134.","journal-title":"Science"},{"key":"1333_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/oby.24235","volume":"33","author":"SJ Athinarayanan","year":"2025","unstructured":"Athinarayanan SJ, Volek JS. Mitigating muscle loss during weight loss: can nutritional ketosis make a difference? A call for more research. Obesity. 2025;33:431\u20134.","journal-title":"Obesity"},{"key":"1333_CR61","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1177\/088307380001501203","volume":"15","author":"DL Gilbert","year":"2000","unstructured":"Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. J Child Neurol. 2000;15:787\u201390.","journal-title":"J Child Neurol"},{"key":"1333_CR62","doi-asserted-by":"crossref","unstructured":"Akgoc Z, Mukherjee P, Seyfried TN. The Glucose Ketone Index predicts overall survival and metastasis of mouse tumor cells tovisceral organs and brain. Longhua Chin Med. 2022;5.","DOI":"10.21037\/lcm-21-43"},{"key":"1333_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/nu12051473","author":"K Hagihara","year":"2020","unstructured":"Hagihara K, Kajimoto K, Osaga S, Nagai N, Shimosegawa E, Nakata H, et al. Promising effect of a new ketogenic diet regimen in patients with advanced cancer. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12051473.","journal-title":"Nutrients"},{"key":"1333_CR64","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s11064-017-2253-5","volume":"42","author":"TA Simeone","year":"2017","unstructured":"Simeone TA, Simeone KA, Rho JM. Ketone bodies as anti-seizure agents. Neurochem Res. 2017;42:2011\u20138.","journal-title":"Neurochem Res"},{"key":"1333_CR65","doi-asserted-by":"crossref","unstructured":"Poff AM, Rho JM, D\u2019Agostino DP. Ketone administration for seizure disorders: history and rationale for ketone esters and metabolic alternatives.\u00a0Front Neurosci. 2019;13:1041.","DOI":"10.3389\/fnins.2019.01041"},{"key":"1333_CR66","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clnesp.2023.01.030","volume":"54","author":"A Buga","year":"2023","unstructured":"Buga A, Kackley ML, Crabtree CD, Bedell TN, Robinson BT, Stoner JT, et al. Fasting and diurnal blood ketonemia and glycemia responses to a six-week, energy-controlled ketogenic diet, supplemented with racemic R\/S-BHB salts. Clin Nutr ESPEN. 2023;54:277\u201387.","journal-title":"Clin Nutr ESPEN"},{"key":"1333_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/nu13030966","volume":"13","author":"CD Crabtree","year":"2021","unstructured":"Crabtree CD, Kackley ML, Buga A, Fell B, LaFountain RA, Hyde PN, et al. Comparison of ketogenic diets with and without ketone salts versus a low-fat diet: liver fat responses in overweight adults. Nutrients. 2021;13: 13:966.","journal-title":"Nutrients"},{"key":"1333_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0026-0495(83)90106-3","volume":"32","author":"SD Phinney","year":"1983","unstructured":"Phinney SD, Bistrian BR, Evans WJ, Gervino E, Blackburn GL. The human metabolic response to chronic ketosis without caloric restriction: preservation of submaximal exercise capability with reduced carbohydrate oxidation. Metabolism. 1983;32:769\u201376.","journal-title":"Metabolism"},{"key":"1333_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","volume":"66","author":"BC Lupsa","year":"2023","unstructured":"Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia. 2023;66:23\u201332.","journal-title":"Diabetologia"},{"key":"1333_CR70","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/met.2021.0042","volume":"20","author":"N Tzenios","year":"2022","unstructured":"Tzenios N, Lewis ED, Crowley DC, Chahine M, Evans M. Examining the efficacy of a very-low-carbohydrate ketogenic diet on cardiovascular health in adults with mildly elevated low-density lipoprotein cholesterol in an open-label pilot study. Metab Syndr Relat Disord. 2022;20:94\u2013103.","journal-title":"Metab Syndr Relat Disord"},{"key":"1333_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128308","volume":"4","author":"PN Hyde","year":"2019","unstructured":"Hyde PN, Sapper TN, Crabtree CD, LaFountain RA, Bowling ML, Buga A, et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight. 2019;4: e128308.","journal-title":"JCI Insight"},{"key":"1333_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.618520","author":"A Buga","year":"2021","unstructured":"Buga A, Kackley ML, Crabtree CD, Sapper TN, Mccabe L, Fell B, et al. The effects of a 6-week controlled, hypocaloric ketogenic diet, with and without exogenous ketone salts, on body composition responses. Front Nutr. 2021. https:\/\/doi.org\/10.3389\/fnut.2021.618520.","journal-title":"Front Nutr"},{"key":"1333_CR73","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.70397","volume":"13","author":"CD Crabtree","year":"2025","unstructured":"Crabtree CD, Stoner J, Buga A, Robinson B, Decker D, Chebbi A, et al. Cardiopulmonary responses to acute exogenous ketosis at rest, and during submaximal and maximal exercise. Physiol Rep. 2025;13: e70397.","journal-title":"Physiol Rep"},{"key":"1333_CR74","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/07315724.2021.2015476","volume":"42","author":"CD Crabtree","year":"2023","unstructured":"Crabtree CD, Blade T, Hyde PN, Buga A, Kackley ML, Sapper TN, et al. Bis hexanoyl (R)-1,3-butanediol, a novel ketogenic ester, acutely increases circulating r- and s-\u00df-hydroxybutyrate concentrations in healthy adults. Journal of the American Nutrition Association. 2023;42:169\u201377.","journal-title":"Journal of the American Nutrition Association"},{"key":"1333_CR75","doi-asserted-by":"publisher","DOI":"10.3945\/cdn.117.000851","volume":"1","author":"A Courchesne-Loyer","year":"2017","unstructured":"Courchesne-Loyer A, Lowry C-M, St-Pierre V, Vandenberghe C, Fortier M, Castellano C-A, et al. Emulsification increases the acute ketogenic effect and bioavailability of medium-chain triglycerides in humans. Curr Dev Nutr. 2017;1: e000851.","journal-title":"Curr Dev Nutr"},{"key":"1333_CR76","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0021-9258(18)62443-3","volume":"246","author":"JD McGarry","year":"1971","unstructured":"McGarry JD, Foster DW. The regulation of ketogenesis from octanoic acid. The role of the tricarboxylic acid cycle and fatty acid synthesis. J Biol Chem. 1971;246:1149\u201359.","journal-title":"J Biol Chem"},{"key":"1333_CR77","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/00365516809076994","volume":"21","author":"L Hagenfeldt","year":"1968","unstructured":"Hagenfeldt L, Wahren J. Human forearm muscle metabolism during exercise. II. Uptake, release and oxidation of individual FFA and glycerol. Scand J Clin Lab Invest. 1968;21:263\u201376.","journal-title":"Scand J Clin Lab Invest"},{"key":"1333_CR78","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1172\/JCI106639","volume":"50","author":"OE Owen","year":"1971","unstructured":"Owen OE, Reichard GA. Human forearm metabolism during progressive starvation. J Clin Invest. 1971;50:1536\u201345.","journal-title":"J Clin Invest"},{"key":"1333_CR79","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1042\/cs0780579","volume":"78","author":"M Elia","year":"1990","unstructured":"Elia M, Wood S, Khan K, Pullicino E. Ketone body metabolism in lean male adults during short-term starvation, with particular reference to forearm muscle metabolism. Clin Sci (Lond). 1990;78:579\u201384.","journal-title":"Clin Sci (Lond)"},{"key":"1333_CR80","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cmet.2018.02.011","volume":"27","author":"L Rajman","year":"2018","unstructured":"Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27:529\u201347.","journal-title":"Cell Metab"},{"key":"1333_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1195702","volume":"14","author":"J Lowder","year":"2023","unstructured":"Lowder J, Fallah S, Venditti C, Musa-Veloso K, Kotlov V. An open-label, acute clinical trial in adults to assess ketone levels, Gastrointestinal tolerability, and sleepiness following consumption of (R)-1,3-butanediol (Avela\u2122). Front Physiol. 2023;14: 1195702.","journal-title":"Front Physiol"},{"key":"1333_CR82","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.1038\/s41598-025-88963-9","volume":"15","author":"C Saenz","year":"2025","unstructured":"Saenz C, Lavin KM, Lee EC, Maresh CM, Kraemer WJ, Bamman MM, et al. Muscle transcriptome profiles in elite male ultra-endurance athletes acclimated to a high-carbohydrate versus low-carbohydrate diet. Sci Rep. 2025;15:8419.","journal-title":"Sci Rep"},{"key":"1333_CR83","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/07315724.2020.1752846","volume":"39","author":"ML Kackley","year":"2020","unstructured":"Kackley ML, Short JA, Hyde PN, LaFountain RA, Buga A, Miller VJ, et al. A Pre-Workout supplement of ketone salts, caffeine, and amino acids improves High-Intensity exercise performance in Keto-Na\u00efve and Keto-Adapted individuals. J Am Coll Nutr. 2020;39:290\u2013300.","journal-title":"J Am Coll Nutr"},{"key":"1333_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0026-0495(75)90004-9","volume":"24","author":"DG Sapir","year":"1975","unstructured":"Sapir DG, Owen OE. Renal conservation of ketone bodies during starvation. Metabolism. 1975;24:23\u201333.","journal-title":"Metabolism"},{"key":"1333_CR85","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1172\/JCI105481","volume":"45","author":"GF Cahill","year":"1966","unstructured":"Cahill GF, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy PL, et al. Hormone-fuel interrelationships during fasting. J Clin Invest. 1966;45:1751\u201369.","journal-title":"J Clin Invest"},{"key":"1333_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","volume":"37","author":"JC Newman","year":"2017","unstructured":"Newman JC, Verdin E. \u03b2-hydroxybutyrate: a signaling metabolite. Annu Rev Nutr. 2017;37:51\u201376.","journal-title":"Annu Rev Nutr"},{"key":"1333_CR87","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.lfs.2005.07.013","volume":"78","author":"Y-C Tsai","year":"2006","unstructured":"Tsai Y-C, Chou Y-C, Wu A-B, Hu C-M, Chen C-Y, Chen F-A, et al. Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes. Life Sci. 2006;78:1385\u201391.","journal-title":"Life Sci"},{"key":"1333_CR88","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1016\/j.jchromb.2011.07.038","volume":"879","author":"W-Y Hsu","year":"2011","unstructured":"Hsu W-Y, Kuo C-Y, Fukushima T, Imai K, Chen C-M, Lin P-Y, et al. Enantioselective determination of 3-hydroxybutyrate in the tissues of normal and streptozotocin-induced diabetic rats of different ages. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:3331\u20136.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1333_CR89","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033628","volume":"13","author":"N Gopalasingam","year":"2024","unstructured":"Gopalasingam N, Moeslund N, Christensen KH, Berg-Hansen K, Seefeldt J, Homilius C, et al. Enantiomer\u2010specific cardiovascular effects of the ketone body 3\u2010hydroxybutyrate. J Am Heart Assoc. 2024;13: e033628.","journal-title":"J Am Heart Assoc"},{"key":"1333_CR90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0003-9861(87)90480-2","volume":"259","author":"BC Lincoln","year":"1987","unstructured":"Lincoln BC, Des Rosiers C, Brunengraber H. Metabolism of S-3-hydroxybutyrate in the perfused rat liver. Arch Biochem Biophys. 1987;259:149\u201356.","journal-title":"Arch Biochem Biophys"},{"key":"1333_CR91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.expneurol.2007.12.029","volume":"211","author":"ML Haces","year":"2008","unstructured":"Haces ML, Hern\u00e1ndez-Fonseca K, Medina-Campos ON, Montiel T, Pedraza-Chaverri J, Massieu L. Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. Exp Neurol. 2008;211:85\u201396.","journal-title":"Exp Neurol"},{"key":"1333_CR92","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: A report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:1757\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"1333_CR93","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47:S158\u201378.","DOI":"10.2337\/dc24-S009"},{"key":"1333_CR94","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47:S179\u2013218.","DOI":"10.2337\/dc24-S010"},{"key":"1333_CR95","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47:S219\u201330.","DOI":"10.2337\/dc24-S011"},{"key":"1333_CR96","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1333_CR97","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"1333_CR98","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"1333_CR99","first-page":"136","volume":"67","author":"ESC Guidelines on","year":"2014","unstructured":"ESC Guidelines on. diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Revista Espa\u00f1ola de cardiolog\u00eda. (English Edition). 2014;67:136.","journal-title":"(English Edition)"},{"key":"1333_CR100","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people. Lancet Diabetes Endocrinol. 2015;3:105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1333_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOMEw trial. Eur Heart J. 2016. https:\/\/doi.org\/10.1093\/eurheartj\/ehv728","journal-title":"Eur Heart J"},{"key":"1333_CR102","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1333_CR103","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138:458\u201368.","journal-title":"Circulation"},{"key":"1333_CR104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci. 2019;4:15\u201326.","journal-title":"JACC Basic Transl Sci"},{"key":"1333_CR105","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10741-021-10083-z","volume":"27","author":"M Barbarawi","year":"2022","unstructured":"Barbarawi M, Al-abdouh A, Barbarawi O, Lakshman H, Al kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2022;27:951\u201360.","journal-title":"Heart Fail Rev"},{"key":"1333_CR106","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1333_CR107","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1333_CR108","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1333_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100725","volume":"33","author":"JL Benham","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. IJC Heart & Vasculature. 2021;33: 100725.","journal-title":"IJC Heart & Vasculature"},{"key":"1333_CR110","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"1333_CR111","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","volume":"4","author":"JHY Wu","year":"2016","unstructured":"Wu JHY, Foote C, Blomster J, Toyama T, Perkovic V, Sundstr\u00f6m J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1333_CR112","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4250\/jcvi.2021.0159","volume":"30","author":"CF Wee","year":"2022","unstructured":"Wee CF, Teo YH, Teo YN, Syn NL, See RM, Leong S, et al. Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiac imaging parameters: A systematic review and Meta-analysis of randomized controlled trials. J Cardiovasc Imaging. 2022;30:153\u201368.","journal-title":"J Cardiovasc Imaging"},{"key":"1333_CR113","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to Sodium\u2013Glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"1333_CR114","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/dom.13224","volume":"20","author":"D Polidori","year":"2018","unstructured":"Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor Canagliflozin. Diabetes Obes Metab. 2018;20:1321\u20136.","journal-title":"Diabetes Obes Metab"},{"key":"1333_CR115","doi-asserted-by":"publisher","first-page":"e028232","DOI":"10.1161\/JAHA.122.028232","volume":"12","author":"R Nielsen","year":"2023","unstructured":"Nielsen R, Christensen KH, Gopalasingam N, Berg-Hansen K, Seefeldt J, Homilius C, et al. Hemodynamic effects of ketone bodies in patients with pulmonary hypertension. J Am Heart Association. 2023;12:e028232.","journal-title":"J Am Heart Association"},{"key":"1333_CR116","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.echo.2021.10.017","volume":"35","author":"S Selvaraj","year":"2022","unstructured":"Selvaraj S, Hu R, Vidula MK, Dugyala S, Tierney A, Ky B, et al. Acute echocardiographic effects of exogenous ketone administration in healthy participants. J Am Soc Echocardiogr. 2022;35:305\u201311.","journal-title":"J Am Soc Echocardiogr"},{"key":"1333_CR117","doi-asserted-by":"crossref","unstructured":"Berg -Hansen, Kristoffer, Christensen KH, Gopalasingam N, Nielsen R, Eiskj \u00e6r H, M, \u00f8ller N et al. Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock. JACC: Heart Failure. 2023;11:1337\u201347.","DOI":"10.1016\/j.jchf.2023.05.029"},{"key":"1333_CR118","first-page":"1440","volume":"135","author":"AP Oneglia","year":"2023","unstructured":"Oneglia AP, Young BE, Cipher DJ, Zaha V, Nelson MD. Acute effects of \u03b2-hydroxybutyrate on left ventricular function in young, healthy adults. J Appl Physiol (1985). 2023;135:1440\u20135.","journal-title":"J Appl Physiol (1985)"},{"key":"1333_CR119","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-023-01008-y","volume":"118","author":"C Homilius","year":"2023","unstructured":"Homilius C, Seefeldt JM, Axelsen JS, Pedersen TM, S\u00f8rensen TM, Nielsen R, et al. Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility. Basic Res Cardiol. 2023;118: 37.","journal-title":"Basic Res Cardiol"},{"key":"1333_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1131192","author":"HZ Wodschow","year":"2023","unstructured":"Wodschow HZ, Davidovski FS, Christensen J, Lassen MCH, Skaarup KG, Nygaard H, et al. Oral ketone esters acutely improve myocardial contractility in post-hospitalized COVID-19 patients: a randomized placebo-controlled double-blind crossover study. Front Nutr. 2023. https:\/\/doi.org\/10.3389\/fnut.2023.1131192.","journal-title":"Front Nutr"},{"key":"1333_CR121","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.123.067971","volume":"149","author":"K Berg-Hansen","year":"2024","unstructured":"Berg-Hansen K, Gopalasingam N, Christensen KH, Ladefoged B, Andersen MJ, Poulsen SH, et al. Cardiovascular effects of oral ketone ester treatment in patients with heart failure with reduced ejection fraction: a randomized, controlled, double-blind trial. Circulation. 2024;149:1474\u201389.","journal-title":"Circulation"},{"key":"1333_CR122","volume":"18","author":"K Berg-Hansen","year":"2025","unstructured":"Berg-Hansen K, Gopalasingam N, Christensen KH, Svart M, Rittig N, Nielsen R, et al. Neurohormonal and renal effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction. Circulation: Heart Failure. 2025;18: e012167.","journal-title":"Circulation: Heart Failure"},{"key":"1333_CR123","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.124.069732","volume":"150","author":"N Gopalasingam","year":"2024","unstructured":"Gopalasingam N, Berg-Hansen K, Christensen KH, Ladefoged BT, Poulsen SH, Andersen MJ, et al. Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction. Circulation. 2024;150:1570\u201383.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01333-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:47:35Z","timestamp":1757450855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01333-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01333-8","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal subjects were used in this review. All studies with human subjects are published and followed ethical, institutional standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"JSV is a cofounder and has equity in Virta Health, is a science advisory for Simply Good Foods, and has published books on low-carbohydrate diets.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"85"}}